ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. announced the filing of a prospectus supplement for its existing "at the market offering" (ATM Program). This program allows the company to offer and sell shares of its common stock with an aggregate offering price of up to $250,000,000. The sales will be conducted through Jefferies LLC as the sales agent, pursuant to an Open Market Sale Agreement dated February 3, 2025.

ArriVent BioPharma reported a reduced net loss of $43.3 million for the first quarter of 2026, compared to $64.4 million in the prior year, with net loss per share improving to $(0.96). Research and development expenses decreased to $37.6 million, while general and administrative expenses increased to $8.5 million. The company's cash and cash equivalents rose to $62.1 million, with total cash and marketable securities at $326.4 million. Additionally, ArriVent received US IND clearance for ARR-002, expecting to initiate a Phase 1 trial in the second half of 2026, and incurred a $6.0 million developmental milestone payment to Lepu Biopharma.

ArriVent BioPharma reported a net loss of $43.3 million for the first quarter ended March 31, 2026, an improvement from $64.4 million in Q1 2025. The company highlighted significant pipeline progress, including expected topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC by mid-2026. Additionally, the Investigational New Drug (IND) application for ARR-002, a dual-targeting ADC, was cleared by the FDA, with plans to dose the first patient in 2H 2026 for ovarian and endometrial cancers. ArriVent also reported $326.4 million in cash and investments, providing a projected cash runway into Q4 2027.

ArriVent BioPharma reported Q1 2026 financial results and provided significant pipeline updates. The company anticipates topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC by mid-2026. Additionally, its dual-targeting ADC, ARR-002, received IND clearance and is slated to dose its first patient in 2H 2026 for ovarian and endometrial cancers. ArriVent also highlighted the NMPA accelerated approval for firmonertinib in China and a strong cash position of $326.4 million, expected to fund operations into Q4 2027.

ArriVent BioPharma, Inc. announced that the FDA has cleared its Investigational New Drug (IND) application for ARR-002, a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate (ADC). The company plans to initially focus ARR-002 on ovarian and endometrial cancers, with broader therapeutic potential across solid tumors. Preclinical data presented at AACR demonstrated superior efficacy and favorable tolerability compared to single-target approaches. ArriVent anticipates initiating a Phase 1 trial and dosing the first patient in the second half of 2026.

ArriVent BioPharma, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 18, 2026. Key proposals include the election of three directors to serve three-year terms and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026. The board of directors recommends approval for both proposals. The filing also detailed significant beneficial ownership, with Infinitum Asset Management, LLC, Hillhouse Investment Management, Ltd., and Suvretta Capital Management, LLC being among the largest holders.